Clinical Performance Evaluation for IVDs In India

Clinical performance evaluation for IVDs ensures that in vitro diagnostic devices introduced into the Indian market provide accurate, reliable, and clinically meaningful results. Manufacturers can demonstrate the diagnostic value of their products while supporting patient safety and effective disease detection by following the regulatory requirements established under Medical Device Rules, 2017, and generating robust clinical evidence.

Clinical Performance Evaluation For IVDs

In vitro diagnostic devices (IVDs) play a crucial role in disease detection, screening, and monitoring. In India, many IVDs must undergo clinical performance evaluation before regulatory approval for marketing to ensure their safety, reliability, and clinical utility.

This article explains the regulatory framework, steps, and best practices for conducting IVD clinical performance evaluation in India

Regulatory Framework for IVD Clinical Performance Evaluation

In India, IVDs are regulated as Medical Devices under the Drugs and Cosmetics Act and the Medical Devices Rules (MDR), 2017. The Central Licensing Authority (CLA), operating under the Central Drugs Standard Control Organisation (CDSCO), is responsible for approving clinical performance studies for new IVDs.

The purpose of IVD clinical performance evaluation studies is to establish or confirm that the device performs as intended when tested on humans, particularly in situations where this cannot be adequately demonstrated using analytical performance data, published literature, or evidence derived from routine diagnostic use. The study design may be interventional, observational, or a combination, depending on whether study protocol requires patient management based on test results. The studies assess parameters such as diagnostic sensitivity, specificity, accuracy, and reproducibility.

CDSCO IVD clinical trials require manufacturers to submit a performance evaluation report (PER) that compiles clinical evidence supporting the device’s intended use.

When Is Clinical Performance Evaluation Of In Vitro Diagnostic Kits Required?

Under MDR, 2017, clinical performance evaluation is typically required for higher-risk IVDs, especially:

Class B, C, and D IVDs without predicate devices
Novel diagnostic technologies
Devices claiming new clinical indications

Note: For low-risk Class A IVDs, clinical performance evaluation of IVD may not be required unless deemed necessary by the CLA based on the nature of the IVD. The reasons for this decision should be recorded in writing. Examples of devices in this category include specimen receptacles and simple clinical chemistry analysers that can perform routine assays like glucose measurement.

Clinical Performance Evaluation Process for IVDs in India

The performance evaluation process involves several regulatory and scientific steps to ensure the diagnostic accuracy, safety, and reliability of the device before it is approved for marketing.

Figure1

Development of a Clinical Performance Evaluation Plan

The first step is the preparation of a clinical performance evaluation plan. This document outlines the purpose of the study, along with the scientific, technical, and medical grounds for conducting the evaluation, and clearly defines the scope of the performance assessment.

Regulatory Application to CDSCO

Before initiating the study, the sponsor must obtain permission from the CLA under CDSCO.

As per the MDR, 2017, an application to conduct a clinical performance evaluation of a new IVD must be submitted to the CLA in Form MD-24 IVD application by the sponsor, along with the prescribed fee specified in the Second Schedule and the required supporting information. After reviewing the submitted documents, CDSCO may grant approval in Form MD-25, allowing the sponsor to initiate the study.

Ethics Committee Approval and Trial Registration

Ethical oversight is mandatory for all clinical performance studies involving human specimens. The study protocol must be approved by a registered ethics committee before patient samples are collected.

Additionally, the study must be registered in the Clinical Trials Registry of India (CTRI) prior to enrolment of the first participant. This registration ensures transparency and allows public access to key details about the clinical investigation.

Conduct of the Clinical Performance Study of IVD

Once IVD regulatory compliance in India is obtained, the clinical performance study can begin. These studies must be conducted in accordance with:

Good Clinical Practice (GCP) guidelines
Approved study protocol
Requirements under MDR, 2017

Clinical performance studies assess the diagnostic accuracy of an IVD by comparing its results with a reference standard method. Several parameters are used to assess the clinical performance of the device (Table 1).These parameters collectively help determine whether the diagnostic device provides reliable and clinically meaningful results for its intended use.

Additional assessments, such as reproducibility, cross-reactivity, and interference testing, may also be performed depending on the type of IVD diagnostic device study in India

Parameter	Definition
Diagnostic Sensitivity	The ability of a diagnostic device to correctly identify a target marker for a condition (expressed as a percentage of individuals with the target disease who test positive).
Diagnostic Specificity	The ability of a diagnostic device to correctly identify the absence of a target marker of a specific condition (expressed as a percentage of individuals who do not have the target disease or condition who test negative).
Positive Predictive Value (PPV)	The ability of the device to identify the proportion of individuals with true positive results who truly have the disease.
Negative Predictive Value (NPV)	The ability of the device to identify the proportion of individuals with true negative results who truly do not have the disease.
Likelihood Ratio	The likelihood of getting a test result in a person with a target health condition compared to the likelihood of getting the same result in a person without the target health condition.

Table 1: Key clinical performance parameters

Data Analysis and PER

After completion of the clinical performance study, the collected data are statistically analysed to determine whether the device meets predefined performance criteria. The findings are compiled into a PER.

Typically, the PER includes key information such as the product name, batch or lot number, manufacturer and importer details, number of samples tested, testing principle, reference method used, and testing procedure.

The report also summarises important performance indicators, including sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), repeatability, reproducibility, and accuracy, along with the report number, date of analysis, and signatures of the analyst and authorised laboratory signatory.

Regulatory Submission and Approval

The final PER, along with other technical and quality documentation, is submitted to CDSCO as part of the device licensing application.

Regulators review the evidence to confirm that the device demonstrates adequate clinical performance, reliability, and safety for its intended diagnostic use. If the evidence is satisfactory, the device may be granted approval for marketing in India.

Conclusion

Clinical performance evaluation of IVD is a critical step in demonstrating the safety, accuracy, and clinical utility of IVDs in India. The process spans from developing a clinical performance evaluation plan to conducting the study and compiling a PER to ensure that the diagnostic device performs reliably in real clinical settings.

Manufacturers can generate credible clinical evidence supporting the intended use of their diagnostic devices by adhering to the requirements established by CDSCO. This structured evaluation process ultimately supports the clinical validation of IVD diagnostic tests, ensuring that only accurate and reliable diagnostics are introduced into the Indian healthcare system.

References

Ramesh M, Sah H, C A. Regulatory Framework for In Vitro Diagnostic Devices in India: Current Landscape, Challenges, and Future Perspectives. J Appl Lab Med 2026;11(1):125-142. doi:10.1093/jalm/jfaf164
Medical Devices Rules, 2017.pdf. Accessed March 12, 2026. https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2022/m_device/Medical%20Devices%20Rules,%202017.pdf
Leeflang MMG, Allerberger F. How to: evaluate a diagnostic test. Clin Microbiol Infect. 2019;25(1):54-59. doi:10.1016/j.cmi.2018.06.011
GHTF SG5 Clinical Performance Studies for IVD Medical Devices. Accessed March 24, 2026. https://www.imdrf.org/sites/default/files/docs/ghtf/final/sg5/technical-docs/ghtf-sg5-n8-2012-clinical-performance-studies-ivd-medical-devices-121102.pdf
Manu M, Anand G. A review of medical device regulations in India, comparison with European Union and way-ahead. Perspect Clin Res. 2022;13(1):3-11. doi:10.4103/picr.PICR_222_20
CDSCO-IVD-FAQ-03-2022-.pdf. Accessed March 12, 2026. https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/IVD/FAQs/CDSCO-IVD-FAQ-03-2022-.pdf
FAaddendum.pdf. Accessed March 12, 2026. https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/FAaddendum.pdf